Read by QxMD icon Read


Sang Hyun Choi, Jae Ho Byun, Young-Suk Lim, So Jung Lee, So Yeon Kim, Hyung Jin Won, Yong Moon Shin, Pyo-Nyun Kim
Purpose To determine the outcomes after initial therapy in patients with chronic liver disease and retrospectively assigned Liver Imaging Reporting and Data System (LI-RADS; version 2014) category 4 (LR-4) and 5 (LR-5) nodules at gadoxetate disodium-enhanced MR imaging. Materials and Methods In this retrospective study, 260 patients with a single LR-4 (n = 132) or LR-5 (n = 128) nodule who were assigned a LI-RADS category were included. Patients were identified between January 2012 and December 2012, and were initially treated by resection, liver transplant, radiofrequency ablation (RFA), or transcatheter arterial chemoembolization (TACE) according to the Barcelona Clinic Liver Cancer staging system...
February 19, 2018: Radiology
Amanda R Smolock, Mircea M Cristescu, Audrey Hinshaw, Kaitlin M Woo, Shane A Wells, Timothy J Ziemlewicz, Meghan G Lubner, Prasad S Dalvie, J Louis Hinshaw, Christopher L Brace, Orhan S Ozkan, Fred T Lee, Paul Laeseke
PURPOSE: To compare transarterial chemoembolization (TACE) monotherapy to combination TACE and microwave ablation (MWA) for local control of 3- to 5-cm hepatocellular carcinoma (HCC). METHODS: Patients with HCC between 3 and 5 cm treated with TACE monotherapy or combination TACE + MWA at a single institution between 2007 and 2016 were retrospectively reviewed. Twenty-four HCCs (median diameter 3.8 cm) in 16 patients (13 males; median age 64 years) were treated using TACE monotherapy...
February 15, 2018: Abdominal Radiology
Tatjana Gruber-Rouh, Cornelia Schmitt, Nagy N N Naguib, N A Nour-Eldin, Katrin Eichler, Martin Beeres, Thomas J Vogl
BACKGROUND: To evaluate survival data and local tumor control after transarterial chemoembolization in two groups with different embolization protocols for the treatment of HCC patients. METHODS: Ninty-nine patients (mean age: 63.6 years), 78 male (78.8%) with HCC were repeatedly treated with chemoembolization in 4-week-intervals. Eighty-eight patients had BCLC-Stage-B and in 11 patients, chemoembolization was performed for bridging (BCLC-Stage-A). In total, 667 chemoembolization treatments were performed (mean 6...
February 14, 2018: BMC Cancer
Michael Praktiknjo, Viktoria Krabbe, Alessandra Pohlmann, Matthias Sampels, Christian Jansen, Carsten Meyer, Christian P Strassburg, Jonel Trebicka, Maria A Gonzalez Carmona
BACKGROUND: Early information on treatment response of HCC to local ablative therapy is crucial. Elastography as a non-invasive method has recently been shown to play a potential role in distinguishing between benign and malignant liver lesions. Elastography of hepatocellular carcinoma (HCC) in early response to local ablative therapy has not been studied to date. METHODS: We prospectively included a cohort of 14 patients with diagnosis of HCC who were treated with local ablative therapy (transarterial chemoembolization, TACE and/or radiofrequency ablation, RFA)...
2018: PloS One
Jung Hee Kim, Dong Hyun Sinn, Jeong-Hoon Lee, Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
BACKGROUND: Recently, albumin-bilirubin (ALBI) grade has been suggested as a better surrogate for hepatic functional reserve for patients with hepatocellular carcinoma (HCC). AIMS: We developed and validated a novel prediction model to predict outcome for HCC patients who underwent transcatheter arterial chemoembolization (TACE) as a first-line therapy. METHODS: From a multivariate Cox regression model for overall survival, five objective variables (ALBI grade), the Barcelona clinic liver cancer (BCLC) stage, response after the first TACE session, Alpha-fetoprotein level, and sex were chosen and the ABRAS score was developed from the derivation cohort (n = 476) and scored to generate an 8-point risk prediction model...
February 13, 2018: Digestive Diseases and Sciences
Jin Hyoung Kim, Ju Hyun Shim, Hyun-Ki Yoon, Heung-Kyu Ko, Jong Woo Kim, Dong Il Gwon
BACKGROUND AND AIMS: We evaluated survival outcomes and prognostic factors associated with survival after transarterial chemoembolization (TACE) in a large cohort of 331 patients with hepatocellular carcinoma (HCC) with segmental portal vein tumor thrombosis (PVTT). METHODS: From 1997 to 2015, a total of 331 patients were included in this study from among 507 patients who underwent TACE as a first-line treatment for HCC with segmental PVTT. RESULTS: After TACE, the median survival of the whole cohort was 10...
February 13, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Chaobin He, Yu Zhang, Xiaojun Lin
BACKGROUND: In analyzing cancer patient survival data, the problem of competing risks is often ignored. This study used a competing risk approach to evaluate the efficacy of recombinant human type-5 adenovirus (H101) in patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). METHODS: In this retrospective study, 476 patients were included. The cumulative probabilities of cancer-specific mortalities were analyzed by the Kaplan-Meier (KM) method and a competing risk model...
February 12, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
Young Woon Kim, Jung Hyun Kwon, Soon Woo Nam, Jeong Won Jang, Hyun Suk Jung, Yu Ri Shin, Eun Su Park, Dong Jae Shim
Transarterial chemoembolization (TACE) with drug-eluting beads (DC beads) may enhance drug delivery to tumours and reduce systemic toxicity. TACE with DC beads leads to significantly fewer serious side-effects compared with conventional TACE. A 66-year-old man with hepatocellular carcinoma (HCC) complained of continuous abdominal pain 1 month after TACE with DC beads. At the time of TACE, angiography revealed severe stenosis of both hepatic arteries. The diagnostic work up on admission suggested severe bile duct injury with regional bile duct dilatation, segmental liver and spleen infarction, necrotizing pancreatitis, as well as gastric and duodenal ulcers...
February 2018: Experimental and Therapeutic Medicine
K Malagari, R Iezzi, S N Goldberg, J I Bilbao, A Sami, O Akhan, F Giuliante, M Pompili, L Crocetti, V Valentini, A Gasbarrini, C Colosimo, R Manfredi
Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. The mechanism of action of c-TACE is the induction of tumor necrosis due to the high concentration of the chemotherapeutic that is delivered only locally and to the embolic effect that causes ischemia and increased dwell time of the chemotherapeutic in the tumor. Recently, DEB-TACE has emerged as a variation of c-TACE with the potential for the selective delivery of large amounts of drugs to the tumor for a prolonged period, thereby decreasing plasma levels of the chemotherapeutic agent and related systemic effects...
January 2018: European Review for Medical and Pharmacological Sciences
Jian Zhou, Zheng Wang, Zhenggang Ren, Yi Chen, Jie Hu, Guo-Huan Yang, Lei Yu, Xin-Rong Yang, Ao Huang, Xin Zhang, Shao Lai Zhou, Hui-Chuan Sun, Yan Hong Wang, Ning Ling Ge, Xiao-Yu Xu, Zhaoyou Tang, Wan Yee Lau, Jia Fan, Jiping Wang
PURPOSE: The survival of patients with hepatocellular carcinoma (HCC) recurrence after curative resection are usually poor. We sought to evaluate the safety and efficacy of adjuvant transarterial chemoembolization (TACE) in HBV-related HCC patients with an intermediate (a single tumor larger than 5 cm without microvascular invasion) or high risk (a single tumor with microvascular invasion, or two or three tumors) of recurrence. EXPERIMENTAL DESIGN: In this randomized phase 3 trial, 280 eligible patients were assigned to adjuvant TACE (n=140) or no adjuvant treatment (control; n = 140) groups...
February 2, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Xiaojun He, Xiaopeng Guo, Hongsen Zhang, Xiangchuang Kong, Fan Yang, Chuansheng Zheng
TACE (transcatheter arterial chemoembolization) has been recognized as an effective palliative treatment option for patients with HCC, however, the medium-long term efficacy of it remains modest. LY2109761, a TGF-β receptor inhibitor, was confirmed to reduce tumor cell growth, intravasation, and metastatic dissemination of HCC cells through different molecular mechanisms. This study aims to investigate the treatment effect of combining TACE therapy with LY2109761- a TGF-β receptor I kinase inhibitor on suppressing tumor growth and metastasis in a rabbit VX2 tumor model...
January 2, 2018: Oncotarget
Masashi Hirooka, Atsushi Hiraoka, Hironori Ochi, Yoshiyasu Kisaka, Kouji Joko, Kojiro Michitaka, Yoichi Hiasa
OBJECTIVE: The objective of our study was to clarify the indications for transcatheter arterial chemoembolization (TACE) of the hepatic artery combined with radiofrequency ablation (RFA), which we refer to as "TACE-RFA," for patients with hepatocellular carcinoma (HCC) beyond the Milan criteria. This study assessed the prognoses of patients with intermediate-stage HCC, which we defined as Barcelona Clinic Liver Cancer (BCLC) stage B (hereafter referred to as BCLC-B), according to the BCLC-B substages through treatment in a multicenter study...
February 7, 2018: AJR. American Journal of Roentgenology
Jared A White, Stephen H Gray, Peng Li, Heather N Simpson, Brendan M McGuire, Devin E Eckhoff, Ahmed Mohamed Kamel Abdel Aal, Souheil Saddekni, Derek A Dubay
Transarterial chemoembolization (TACE) is the most common oncologic therapy used according to the American Association for the Study of Liver Diseases (AASLD) guidelines established in 2005, revised in 2011. The purpose of this study was to determine how AASLD criteria for the management of hepatocellular carcinoma (HCC) have impacted TACE practice in the community. Clinical, demographic, and cause of death information were collected for patients diagnosed with HCC in the 2012 linkage of the Surveillance, Epidemiology, and End Results Medicare database...
June 2017: Hepatology Communications
Zhan-Hong Chen, Ying-Fen Hong, Xiangwei Chen, Jie Chen, Qu Lin, Jinxiang Lin, Xing Li, Jing-Yun Wen, Dan-Yun Ruan, Min Dong, Li Wei, Tian-Tian Wang, Ze-Xiao Lin, Xiao-Kun Ma, Dong-Hao Wu, Xiang-Yuan Wu, Ruihua Xu
The majority of patients with unresectable hepatocellular carcinoma (HCC) undergo trans-arterial chemoembolization (TACE). However, the prognosis of HCC remains poor. In the present study, five staging systems were compared to predict the survival rate of patients with HCC undergoing TACE treatment. A total of 220 patients with HCC were examined according to the model to estimate survival for hepatocellular carcinoma (MESH), hepatoma arterial embolization prognostic score (HAP), modified HAP (mHAP), performance status combined Japan Integrated Staging system (PSJIS) and tumor-node-metastasis (TNM) staging systems...
January 2018: Oncology Letters
Yi-Shuan Hwang, Hui-Yu Tsai, Yu-Ying Lin, Kar-Wai Lui
BACKGROUND: To investigate the organ dose, effective dose (ED), conversion factor, and the C-arm rotation angle effects on dose variations of abdominal C-arm cone-beam computed tomography (CBCT) during transarterial chemoembolization (TACE). METHODS: The organ doses and EDs for abdominal C-arm CBCT were retrospectively calculated according to a Monte Carlo technique for 80 patients. Dose variations from projections, ED to dose-area product (DAP) ratios, and effects of body mass index (BMI) on the ED and ED to DAP ratios were also analyzed...
February 5, 2018: BMC Medical Imaging
Jian Zhang, Huizhong Li, Dazhi Gao, Baofu Zhang, Maojin Zheng, Mingyin Lun, Mengxue Wei, Rui Duan, Maomao Guo, Jiajun Hua, Qian Liu, Jin Bai, Hui Liu, Junnian Zheng, Hong Yao
Dendritic cell-cytokine-induced killer (DC-CIK) cell therapy has been experimentally implemented for enhancing anti-tumoral immunity in patients with hepatocellular carcinoma (HCC) undergoing postoperative transcatheter arterial chemoembolization (POTACE). We performed a retrospective study to evaluate the clinical efficacies of DC-CIK cell therapy and its correlations with several immune factors of the primary tumors. The overall survival time of HCC patients with HBV infection in the study group (POTACE plus DC-CIK cell therapy) was significantly longer than that of the control group (POTACE alone)...
February 5, 2018: Cancer Biology & Therapy
Kazue Shiozawa, Manabu Watanabe, Takashi Ikehara, Shuhei Yamamoto, Takashi Matsui, Yoshinori Saigusa, Yoshinori Igarashi, Iruru Maetani
AIM: To assess the usefulness of intra-arterial contrast-enhanced ultrasonography (IAUS) during transarterial chemoembolization (TACE) with drug-eluting beads (DEB) for hepatocellular carcinoma (HCC). METHODS: Thirty two patients with 39 HCC underwent DEB-TACE guided with IAUS, and examined by contrast-enhanced ultrasonography (CEUS) or dynamic CT after DEB-TACE were enrolled in this study. CEUS findings before DEB-TACE and IAUS findings were compared. Treatments judged to be complete and incomplete for lesions were appropriate and insufficient, respectively...
January 27, 2018: World Journal of Hepatology
Xiao-Chun Meng, Bing-Hui Chen, Jing-Jun Huang, Wen-Sou Huang, Ming-Yue Cai, Jing-Wen Zhou, Yong-Jian Guo, Kang-Shun Zhu
AIM: To identify clinical biomarkers that could early predict improved survival in patients with advanced-stage hepatocellular carcinoma (HCC) treated with transarterial chemoembolization combined with sorafenib (TACE-S). METHODS: We retrospectively evaluated the medical records of consecutive patients with advanced-stage HCC who underwent TACE-S from January 2012 to December 2015. At the first follow-up 4-6 wk after TACE-S (median, 38 d; range, 33-45 d), patients exhibiting the modified Response Evaluation Criteria in Solid Tumors (mRECIST)-evaluated complete response, partial response, and stable disease were categorized as early disease control...
January 28, 2018: World Journal of Gastroenterology: WJG
Xuesong Yao, Dong Yan, Xianxian Jiang, Xiao Li, Huiying Zeng, Dezhong Liu, Huai Li
RATIONALE AND OBJECTIVES: The objective of this study was to investigate the impact of a dual-phase cone-beam computed tomography (DP-CBCT)-based navigation imaging during transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in a perspective randomized study. MATERIALS AND METHODS: Forty-two patients with HCC (39 men, 57 ± 9 years, 13 first-time TACE) underwent TACE using three-dimensional image guidance with automatic detection of tumor-feeding vessels computed from DP-CBCT (early and delayed arterial phases)...
February 1, 2018: Academic Radiology
Daiki Soma, Jun Sakata, Takuya Ando, Kizuki Yuza, Hirosuke Ishikawa, Taku Ohashi, Kazuyasu Takizawa, Kabuto Takano, Takashi Kobayashi, Hiroshi Ichikawa, Takaaki Hanyu, Masayuki Nagahashi, Yoshifumi Shimada, Hitoshi Kameyama, Toshifumi Wakai
Lymph node metastasis has a poor prognosis in patients with hepatocellular carcinoma(HCC). We report a case of HCC with lymph node metastasis successfully treated by multidisciplinary treatment. An 81-year-old woman who was followed up for liver cirrhosis received a diagnosis of HCC, which was detected by CT as a solitary tumor 20mm in diameter in the couinaud segment 7 of the liver. She underwent transcatheter arterial chemoembolization(TACE)twice for HCC because of her advanced age and no intention to undergo hepatectomy...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"